Compassionate Use Programs In APAC: China Breaks The Ice
Executive Summary
Compassionate use programs (CUP) are a developing field in Asian countries. In the majority of Asian states, the CU applies to Named-Patients Program (NPP). In the most countries, understanding of CUP for unapproved drugs is poor among the public, and even for professional communities.
You may also be interested in...
Novartis’s Iptacopan Pulls Ahead In Race To Fill Nephrology Unmet Need
The first-in-class candidate met two primary endpoints in a Phase II trial for C3 glomerulopathy, suggesting potential edge over ChemoCentryx and Vifor’s competitor avacopan.
Beauty Multinationals Lean On North America As China’s COVID Shutdowns Upset Growth
China’s “zero-COVID” policy and associated lockdowns were felt deeply in the 2022 first quarter by cosmetics giants in neighboring countries and global market leaders. Effects likely will be more pronounced in Q2.
US FDA To Explore New Regulatory Pathways For Some Cellular Products
Agency re-evaluating criteria for certain human cells, tissues and cellular and tissue-based products (HCT/Ps) that are not ideally regulated as BLAs; industry suggests a 2014 guidance which created an alternative pathway for cord blood products could serve as potential template.